DYAI — Dyadic International Share News
0.000.00%
Last trade - 00:00- $15.99m
- $17.91m
- $3.09m
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development
Brief: Dyadic Announces First Quarter 2026 Financial Results And Highlights Recent Company Progress
Dyadic International Q1 net loss narrows
Dyadic International 2025 revenue falls, net loss widens
Brief: Dyadic Applied Biosolutions Announces Commercial Distribution Partnership With Ibt Bioservices
Brief: Dyadic International Inc - Co And Brig Bio Sign Development And Commercialization Agreement
Brief: Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
Dyadic International Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Dyadic International Announces Pricing Of Public Offering Of 6,052,000 Shares Of Common Stock
Brief: Dyadic International Announces Strategic Rebrand to Dyadic Applied BioSolutions
Dyadic International Inc reports results for the quarter ended December 31 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic To Attend The 43rd Annual J.P. Morgan Healthcare Conference
Brief: Dyadic Receives $3 Million Grant To Develop Cost-Effective Monoclonal Antibodies For Rsv And Malaria Using C1 Platform Technology
Dyadic International Inc reports results for the quarter ended September 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 7 cents a share - Earnings Preview